These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36795846)

  • 1. Modeling Heart Diseases on a Chip: Advantages and Future Opportunities.
    Mourad O; Yee R; Li M; Nunes SS
    Circ Res; 2023 Feb; 132(4):483-497. PubMed ID: 36795846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart-on-a-chip platforms and biosensor integration for disease modeling and phenotypic drug screening.
    Criscione J; Rezaei Z; Hernandez Cantu CM; Murphy S; Shin SR; Kim DH
    Biosens Bioelectron; 2023 Jan; 220():114840. PubMed ID: 36402101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development.
    Davis RP; van den Berg CW; Casini S; Braam SR; Mummery CL
    Trends Mol Med; 2011 Sep; 17(9):475-84. PubMed ID: 21703926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Step-by-step fabrication of heart-on-chip systems as models for cardiac disease modeling and drug screening.
    Deir S; Mozhdehbakhsh Mofrad Y; Mashayekhan S; Shamloo A; Mansoori-Kermani A
    Talanta; 2024 Jan; 266(Pt 1):124901. PubMed ID: 37459786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organ-on-a-chip technology: a novel approach to investigate cardiovascular diseases.
    Paloschi V; Sabater-Lleal M; Middelkamp H; Vivas A; Johansson S; van der Meer A; Tenje M; Maegdefessel L
    Cardiovasc Res; 2021 Dec; 117(14):2742-2754. PubMed ID: 33729461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease Modeling and Disease Gene Discovery in Cardiomyopathies: A Molecular Study of Induced Pluripotent Stem Cell Generated Cardiomyocytes.
    Kumar S; Curran JE; Kumar K; DeLeon E; Leandro AC; Peralta J; Williams-Blangero S; Blangero J
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards chamber specific heart-on-a-chip for drug testing applications.
    Zhao Y; Rafatian N; Wang EY; Wu Q; Lai BFL; Lu RX; Savoji H; Radisic M
    Adv Drug Deliv Rev; 2020; 165-166():60-76. PubMed ID: 31917972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pluripotent Stem Cell-Based Platforms in Cardiac Disease Modeling and Drug Testing.
    Shaheen N; Shiti A; Gepstein L
    Clin Pharmacol Ther; 2017 Aug; 102(2):203-208. PubMed ID: 28718902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Induced Pluripotent Stem-Cell-Derived Cardiomyocytes as Models for Genetic Cardiomyopathies.
    Brodehl A; Ebbinghaus H; Deutsch MA; Gummert J; Gärtner A; Ratnavadivel S; Milting H
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31489928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies.
    Ramachandra CJA; Chua J; Cong S; Kp MMJ; Shim W; Wu JC; Hausenloy DJ
    Cardiovasc Res; 2021 Feb; 117(3):694-711. PubMed ID: 32365198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Ischemia On-a-Chip: Antiarrhythmic Effect of Levosimendan on Ischemic Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Gaballah M; Penttinen K; Kreutzer J; Mäki AJ; Kallio P; Aalto-Setälä K
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells.
    Giacomelli E; Bellin M; Sala L; van Meer BJ; Tertoolen LG; Orlova VV; Mummery CL
    Development; 2017 Mar; 144(6):1008-1017. PubMed ID: 28279973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Untangling the Biology of Genetic Cardiomyopathies with Pluripotent Stem Cell Disease Models.
    Buikema JW; Wu SM
    Curr Cardiol Rep; 2017 Apr; 19(4):30. PubMed ID: 28315121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives for Future Use of Cardiac Microtissues from Human Pluripotent Stem Cells.
    Arslan U; Orlova VV; Mummery CL
    ACS Biomater Sci Eng; 2022 Nov; 8(11):4605-4609. PubMed ID: 35315663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
    Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
    Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generating 3D human cardiac constructs from pluripotent stem cells.
    Liu C; Feng X; Li G; Gokulnath P; Xiao J
    EBioMedicine; 2022 Feb; 76():103813. PubMed ID: 35093634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling heart disease in a dish: from somatic cells to disease-relevant cardiomyocytes.
    Zanella F; Lyon RC; Sheikh F
    Trends Cardiovasc Med; 2014 Jan; 24(1):32-44. PubMed ID: 24054750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspective on human pluripotent stem cell-derived cardiomyocytes in heart disease modeling and repair.
    Li Q; Wang J; Wu Q; Cao N; Yang HT
    Stem Cells Transl Med; 2020 Oct; 9(10):1121-1128. PubMed ID: 32725800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies.
    Brandão KO; Tabel VA; Atsma DE; Mummery CL; Davis RP
    Dis Model Mech; 2017 Sep; 10(9):1039-1059. PubMed ID: 28883014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concise review: reprogramming strategies for cardiovascular regenerative medicine: from induced pluripotent stem cells to direct reprogramming.
    Budniatzky I; Gepstein L
    Stem Cells Transl Med; 2014 Apr; 3(4):448-57. PubMed ID: 24591731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.